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ABSTRACT
Introduction Optimal treatment for ‘potentially resectable’ 
stage III- N2 non- small cell lung cancer (NSCLC) requires 
multimodality treatment: local treatment (surgery or 
radiotherapy) and systemic anticancer therapy. There is 
no clear evidence of superiority for survival between the 
two approaches and little research has explored quality of 
life (QOL). This study will inform the design of a phase III 
randomised trial of surgery versus no surgery as part of 
multimodality treatment for stage III- N2 NSCLC with QOL 
as a primary outcome.
Methods and analysis Patient participants will be 
randomised to receive multimodality treatment 
(1) with surgery OR (2) without surgery. The 
Quintet Recruitment Intervention will be used to 
maximise recruitment. Eligible patients will have 
‘potentially resectable’ N2 NSCLC and have received 
a multidisciplinary team recommendation for 
multimodality treatment. Sixty- six patients and their 
carers will be recruited from 8 UK centres. Patient/carer 
QOL questionnaires will be administered at baseline, 
weeks 6, 9, 12 and month 6. Semistructured interviews 
will be conducted. Quantitative data will be analysed 
descriptively and qualitative data will be analysed using 
framework analysis.
Ethics and dissemination Ethical approval has been 
obtained. Results will be disseminated via publications, 




There are over 46 000 new cases of lung cancer 
every year in the UK and almost 36 000 deaths.1 
The most common histological subtype is non- 
small cell lung cancer (NSCLC) representing 
approximately 80% of all lung cancers. Stage 
III- N2 NSCLC describes lung cancer with nodal 
metastases to the mediastinum on the ipsilateral 
side to the primary tumour. This patient group 
represents approximately 6% of all lung cancer 
cases.2 Curative- intent treatment is recom-
mended for stage III- N2 NSCLC but outcomes 
remain poor with only 15%–20% surviving 
more than 5 years following treatment.2 3 The 
optimal curative- intent treatment for stage 
III- N2 NSCLC requires a combination of (1) 
local treatment (surgery or radiotherapy) for 
local control of the primary tumour and nodal 
disease and (2) systemic anticancer therapy 
with the intention of preventing distant meta-
static disease. Previous randomised controlled 
trials (RCTs) investigating which treatment 
regimen (surgical vs non- surgical) provides the 
best overall survival have failed to show that 
one treatment regimen is markedly superior to 
another.4–7 Furthermore, stage III NSCLC is a 
rapidly changing paradigm. Recent guidelines 
from the National Institute for Health and Care 
Excellence (NICE) have recommended patients 
with Stage III- N2 NSCLC planned for surgical 
management should be considered for chemo-
radiotherapy, followed by surgery (trimodality 
treatment) on the basis of the cost- effectiveness 
of this approach due to an improved progres-
sion free survival of 4.5 months in a network 
meta- analysis.8 Importantly, trimodality treat-
ment did not show a statistically significant 
improvement in overall survival. NICE has 
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also recently approved maintenance Durvalumab (anti 
programmed death ligand 1 (PD- L1)immunotherapy) 
in patients with stage III NSCLC treated with concurrent 
chemoradiotherapy (non- surgical treatment) and a PD- L1 
expression >1%, based on improved overall survival versus 
placebo in a global study assessing the effects ofMEDI4736 
following concurrent chemoradiation (PACIFIC study).9 In 
summary, although it is clear that the optimal treatment for 
stage III- N2 NSCLC is multimodality, including both local 
and systemic treatment, patients and clinicians are faced 
with uncertainty as to the optimal strategy between a surgical 
versus non- surgical approach.
Health-related quality of life in stage III-N2 NSCLC 
treatment
Multimodality treatment in stage III- N2 NSCLC is inten-
sive and may have a considerable impact on patients’ 
health- related quality of life (HRQOL). Given the mark-
edly different treatment pathways between surgery and 
no surgery (radiotherapy) there are likely to be differ-
ences in HRQOL of patients undergoing such treatments. 
However, such metrics are severely lacking from the stage 
III- N2 NSCLC related literature that has largely focused on 
survival outcomes.10 Caregivers play an important role in 
supporting patients’ through treatment decisions and path-
ways.11 12 The small number of studies that have explored 
caregiver HRQOL during lung cancer treatment have 
found evidence of high caregiving burden and reduced 
HRQOL.13–16 However, no research has been conducted to 
explore whether caregiver experience varies depending on 
type of treatment. Having comparative HRQOL and treat-
ment burden information from both patients and caregivers 
undergoing surgical and non- surgical treatment regimens 
for stage III- N2 NSCLC will help future patients, their carers 
and clinicians to make informed decisions about their 
cancer treatment. This is particularly relevant when survival 
outcomes have been shown to be similar and a choice of 
treatment pathway exists. There is, therefore, a clear need 
to study HRQOL in patients and caregivers undergoing 




The PIONEER trial aims to determine the feasibility and 
acceptability of conducting a phase III RCT comparing 
the impact on HRQOL of surgery versus no- surgery as 
part of multimodality treatment, in patients with stage 
III- N2 NSCLC and their carers. Two treatment groups 
will be compared: (1) multimodality treatment including 
surgery or (2) multimodality treatment without surgery. 
This trial, therefore, is focused on those patients with 
stage III- N2 in whom surgery is technically feasible 
(termed ‘potentially resectable’). Patients with stage 
III- N2 in whom the cancer is technically ‘unresectable’ 
are not eligible for the trial and are not the patient cohort 
for whom the decision between surgical and non- surgical 
treatments exist. The following research questions will be 
addressed: (A) what is the total number and proportion 
of patients with ‘potentially resectable’ N2- NSCLC, and 
fit for multimodal therapy, in an unselected population 
of lung cancer patients? (B) Are patients (and carers) 
willing to consent to the study and once randomised do 
they undergo allocated treatment, and if not, why not? 
(C) Are clinicians willing to recruit eligible patients to 
the trial, what are clinician- related barriers/facilitators to 
recruitment? (D) What is the optimum strategy to facil-
itate trial recruitment? (E) What is the optimal primary 
outcome assessment and design for a full phase III trial?
Inclusion and exclusion criteria
Participants are eligible to be included in the study only 
if all of the following criteria apply: Patients with poten-
tially resectable T1-4 N2 M0 NSCLC who have received 
a multidisciplinary team (MDT) recommendation for 
multimodality treatment; MDT consensus that the 
patient has adequate physiological reserve for multimo-
dality treatment and either treatment arm is both tech-
nically and clinically appropriate; patient over the age of 
18 years. Participants are excluded from the study if any 
of the following criteria apply: Patients unable to provide 
informed consent; Patients where the recommendation 
is for treatment other than those multimodality treat-
ments listed; patients in whom a specific multimodality 
treatment regimen is recommended over another by the 
MDT for individualised reasons.
Definition of ‘potentially resectable stage III-N2 NSCLC’
A standardised definition of potentially resectable is 
provided to all sites (box 1). This definition has been 
proposed and validated with a high level of agreement 
in a National survey of practice in stage III lung cancer 
across the UK.17 18 Patients with stage III- N2 NSCLC will 
be deemed ‘potentially resectable’ and eligible for the 
trial if they fulfil all of the criteria set out in the standard-
ised definition.
Box 1 Standardised definition of potentially resectable stage 
III- N2 non- small cell lung cancer
 ► ✓Pathologically confirmed non- small cell lung cancer.
 ► ✓Systematic invasive nodal staging completed (surgical or 
endoscopic).
 ► ✓Thorough radiological staging completed including at least PET- 
CT and contrast enhanced brain imaging.
 ► ✓Primary tumour resectable with high probability of clear patholog-
ical margins and complete resection.
 ► ✓N2 nodal disease is discrete, easily measurable and defined, free 
from major mediastinal structures including the great vessels and 
trachea with no individual lymph node measuring >3 cm.
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Treatment arms
Both treatment arms are offered as standard practice. 
There is no experimental and control arm in this study as 
no one treatment regimen has been found to be clearly 
superior to another and therefore multiple treatment 
options exist as standard of care. This is reflected by 
international lung cancer guidelines which confirm both 
surgical and non- surgical multimodality treatment regi-
mens as appropriate strategies for stage III- N2 NSCLC.19 20
Surgical multimodality treatment arm
The surgical arm can include any form of multimo-
dality treatment that includes surgical resection. This 
includes induction chemotherapy followed by surgery, 
induction chemoradiotherapy followed by surgery and 
surgery followed by adjuvant chemotherapy. The choice 
of surgical multimodality regimen is left to the discretion 
of the local treating MDT. In the UK, surgery followed 
by adjuvant chemotherapy is the most common form of 
multimodality surgical treatment performed and is likely 
to form a significant component of the surgical arm in 
this trial.2 However, the recent NICE guideline recom-
mendation for induction chemoradiotherapy followed 
by surgery may lead to a higher contribution of trimo-
dality treatment to the surgical arm.
Non-surgical multimodality treatment arm
The non- surgical arm can include any form of multi-
modality treatment that does not involve surgery. This 
includes sequential chemoradiotherapy and concurrent 
chemoradiotherapy. Within this treatment arm, there is 
an important discussion point in regards to the use of 
durvalumab following concurrent chemoradiotherapy. 
There is considerable debate among the lung cancer 
community about how the PACIFIC trial results impact 
treatment decisions for patients with stage III NSCLC 
considered suitable for surgery. The PACIFIC trial 
recruited patients with ‘unresectable’ stage III NSCLC 
but the protocol provided no standardised definition 
of ‘unresectable’ and this was left at the discretion of 
the local MDT. Some MDTs consider any N2/medias-
tinal nodal metastases as unresectable whereas other 
MDTs will recommend surgery in N2 NSCLC. In the 
PACIFIC trial, no data were provided to help clinicians 
understand the study population in terms of the extent 
of nodal disease and tumour burden. Everyday practice 
in the UK has reflected this uncertainty with oncologists 
considering the use of durvalumab in patients with stage 
III NSCLC that have completed concurrent chemoradi-
otherapy regardless of whether the disease could have 
been considered technically suitable for surgery at the 
outset, that is, the ‘unresected’ rather than the ‘unresect-
able’. The PIONEER trial provides a standardised defini-
tion of ‘potentially resectable’ N2 NSCLC that is broad 
and will likely include some patients that are similar to 
those treated in the PACIFIC trial. Therefore, if a patient 
within the PIONEER trial is randomised to the non- 
surgical arm and they complete concurrent chemoradi-
otherapy, the local oncologist will consider their eligi-
bility for durvalumab. The local oncologist may wish to 
rediscuss that patient within their local MDT (perhaps 
with the PD- L1 status) to clarify eligibility for durvalumab 
towards the end of the chemoradiotherapy treatment.
Recruitment
The eight recruiting sites will be in Manchester (Wythen-
shawe and Salford), Leeds, Sheffield, University College 
London Hospitals (UCLH), Birmingham, Glasgow and 
Nottingham. There are approximately 2500 new cases of 
N2 NSCLC every year in the UK. Our conservative estimate 
for recruitment is one patient every second month from 
each site. Participants will be eligible for the study if they 
have ‘potentially resectable’ Stage III- N2 lung cancer and 
have received an MDT recommendation for multimodality 
treatment. We aim to recruit 66 patients over a 20- month 
staggered recruitment period. This sample size was chosen 
to ensure that we can estimate key parameters with suffi-
cient precision based on recommendations by Lancaster et 
al.21 Recruitment will be led by the respiratory physicians 
at eight recruiting centres (all high volume lung cancer 
MDTs). The consenting process will be conducted by 
respiratory physicians and supported by lung cancer nurse 
specialists. Our ambition is that the majority of recruitment 
is undertaken by respiratory physicians as impartial advo-
cates for the patient and to minimise treatment related bias. 
However, recruitment within surgical and oncology clinics 
will be allowed to provide flexibility and maximise recruit-
ment opportunities. All potential study participants will be 
provided with a participant information sheet (PIS) and 
invited to voluntarily consent to participate in the study. 
They will also be asked if they have a caregiver who may 
also want to take part in the study. Due to the anticipated 
challenges with recruitment we will proactively monitor, 
evaluate and react to quickly rectify emerging issues. We 
will apply the principles of the Quintet Recruitment Inter-
vention (QRI) to maximise recruitment as much as possible 
and inform the recruitment strategy for the follow- on 
trial.22 Key steps within the QRI process include: (1) 
understanding the recruitment process; (2) documenting 
barriers to recruitment and trying to understand them; 
(3) assessing how the RCT is being delivered by recruiters; 
(4) presenting evidence of recruitment difficulties to the 
trial management group and developing strategies to over-
come these problems and (5) implementing the plan of 
improvement. This will include audio recording of recruit-
ment appointments, with real- time data analysis and feed-
back to the clinical teams to proactively inform recruitment 
practices including ongoing training. We will conduct trial 
recruitment workshop sessions with recruiting clinicians 
across all sites and provide refresher sessions as required 
based on the results of the QRI process.22 Figure 1 presents 
the flow of patients through the study.











es: first published as 10.1136/bm




4 Taylor S, et al. BMJ Open Resp Res 2021;8:e000846. doi:10.1136/bmjresp-2020-000846
Open access
Randomisation
Eligible patients and caregivers will provide written informed 
consent and complete baseline assessments. The recruiting 
clinician will contact the research team at The Christie 
National Health Service Foundation Trust who will manage 
the randomisation process using an online randomisation 
system. The person responsible for randomisation will have 
no involvement in the recruiting process. Participants will 
be randomised on a 1:1 basis to receive either surgery or no 
surgery as part of multimodality treatment. Once a patient 
has been randomised, both the clinical team and the patient 
will be made aware of the treatment allocation; given the 
nature of the intervention there will be no masking of 
patients, carers or clinical staff
Assessments and data collection
Various outcomes and success metrics (table 1) will be 
collected via questionnaires returned by post or completed 
over the telephone by a member of the clinical team. The 
outcomes and success metrics collected will determine if 
it is feasible to do a follow- on randomised controlled trial 
in the future. A summary of required data, assessment 
tools and collection time points is provided in table 2.
Feasibility outcomes
 ► Proportion of patients with N2 disease that are poten-
tially resectable as defined by the lung cancer MDT.
 ► Proportion of patients with potentially resectable N2 
NSCLC that have adequate physiological reserve for 
multimodality treatment.
 ► Number and proportion of eligible patients recruited—
assessment of screening logs to determine numbers 
eligible versus not randomised and reasons (such as 
clinician reluctance, patient/family decline, other).
 ► Proportion of people lost to follow- up due to with-
drawal, death or failure to return questionnaires (ie, 
assessment attrition) by 3 and 6 months by arm.
 ► Percentage of participants with complete data at end 
of trial (6 months), by arm.
Table 1 Feasibility success metrics providing support for a future trial
Green light (proceed with 
minor changes)
Amber light (proceed with 
significant modifications) Red light (do not proceed)
Recruitment 50 or more patients recruited 25–49 patients recruited 24 or fewer patients recruited
Treatment fidelity At least 60% of randomised 
participants receive allocated 
treatments
At least 40% of randomised 
participants receive allocated 
treatments
Less than 40% of 
randomised participants 
receive allocated treatments
Rate of assessment attrition 
at 3 and 6 months
Less than 30% at 3 and 6 
months
Less than 60% at 3 and 6 
months
61% or more at 3 and 6 
months
Qualitative data Positive opinions and/or feasibility recommendations to improve the follow- on trial. We will 
hold an end of study workshop with all coinvestigators, site PIs, patient/carer representatives 
and other stakeholders to present the outcomes and discuss approaches to address issues 
noted as green or amber and reasons for red lights.
Figure 1 CONSORT flow diagram. CONSORT, Consolidated Standards of Reporting Trials; MDT, multidisciplinary team. 
Hospital Anxiety and Depression Scale (HADS). EuroQOL 5 Dimensions (EQ5D)
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 ► Proportion of randomised patients who receive allo-
cated treatment, by arm.
 ► Adherence to the allocated treatment arm will be 
monitored closely (any patients that crossover to 
receive treatment in the other arm will remain in the 
trial for data collection but will be recorded as failing 
to complete the allocated treatment).
 ► Qualitative data recording recruitment consultations 
and interviews with participants and non- participants 
and their carers.
Clinical data
Clinical data will be collected directly from the patients’ 
hospital records. Data collected will include: age; gender; 
performance status at recruitment; clinical frailty score; 
co- morbidities (aligned to the Charlson Comorbidity 
Index); diagnosis of interstitial lung disease; body mass 
index (BMI), smoking status; forced expiratory volume 
(% predicted); diffusing capacity of the lungs for carbon 
monoxide % predicted; blood results at recruitment; 
NSCLC histology; clinical (and pathological where avail-
able) TNM8 staging; location, size and standard uptake 
value (SUV) of primary tumour; N2 nodes involved; N2 
sub classification (single station vs multistation); Highest 
stage N2 nodal size (short axis); Highest stage N2 nodal 
SUVmax and mediastinal blood pool SUVmax. When 
performed the following additional data will be collected, 
accepting this is not mandated: 6 min walk test (metres) 
or incremental shuttle walk (metres); Vo2max (mls/
kg/min) V02max%predicted; left and right ventricular 
function on transthoracic echocardiogram (% ejection 
fraction and/or categorised as normal, mild impairment, 
moderate impairment and severe impairment).
Participant completed data
Patient and caregiver reported outcome measures are 
collected at baseline 6, 9 and 12 weeks and 6 months. 
Unless the participant has a coinciding clinic appoint-
ment, questionnaires will be sent by post. Reminder 
phone calls will be made if questionnaires are not 
returned. Real- time completion of questionnaires via a 
telephone call with research staff may also be considered 
if this is the preference of the patient. Prior to contacting 
the participant by telephone or post, the participants’ 
survival status will be checked with the clinical team. 
Patients and caregivers will also complete diaries 
describing their experiences in more detail.
Qualitative interviews
Qualitative interviews will be conducted at various stages 
of the follow- up process with 12–16 patient and caregiver 
dyads. Participants will be asked at the time of consenting 
to the study if they are happy to be approached to partic-
ipate in an interview. The interview will explore how the 
treatment has impacted on the daily lives of patient and 
caregivers from a practical and psychological perspective, 
their thoughts on the randomisation process and the 
treatment options will also be explored. Interviews will 
last approximately 60 min; they will be audiorecorded 
and transcribed verbatim. Interviews will be conducted 
by a member of The Christie Research team. We will also 
interview 8–10 patients who declined to take part in the 
study or opted not to receive their allocated treatment 
and explore their decision- making processes. Interviews 
will be conducted face to face or over the telephone. A 
topic guide will be developed and interviews audiore-
corded with consent and transcribed verbatim.
Data analysis
Given that this is a feasibility study, we will not conduct 
hypothesis testing to determine if either treatment option 
has a greater impact on HRQOL. Instead, analyses will be 
descriptive, focusing on calculating confidence intervals 
Table 2 Summary of required data, assessment tools, collection time points and processes
Baseline Week 6 Week 9 3 months 6 months
EORTC QLQC30 (plus LC13) X X X X X
SF-36 X X X X X
HADS X X X X X
EQ- 5D X     X X
Service use/health economics questionnaire X     X X
Demographics X         
Clinical data X         
Mortality rates   X X X X
Caregiver outcomes
Carer Quality of Life- Cancer X X X X X
Zarit Caregiver- Burden X X X X X
HADS X X X X X
*European Organisation for Research and Treatment of Cancer (EORTC)
EQ5D, EuroQOL 5 dimensions; HADS, Hospital Anxiety and Depression Scale; SF-36, Short Form Health Survey.
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for key trial parameters.23 For example: (1) estimating 
eligible participant numbers, recruitment, fidelity and 
attrition rates, rate of missing data; (2) estimating the SD 
for HRQOL and likely trajectory over time, in order to 
inform/refine a sample size calculation for a future phase 
III trial and (3) determining whether the study design 
was acceptable to participants and their caregivers. A 
feature of the study data will be that some participants 
will have their HRQOL outcomes censored due to death. 
The study will allow us to estimate the frequency of this 
occurring, and to develop an analytical strategy for a 
phase III trial. We plan to use joint modelling techniques 
(joineR package in R24), which allows for the joint anal-
ysis of survival data and endogenous repeated measures. 
Our analysis will focus on estimating variability, corre-
lation between repeated measurements from the same 
individual and modelling the trajectory of HRQOL over 
time. We will adjust for baseline functional status. We will 
use the data from this study to design a detailed analysis 
plan for a confirmatory study. Qualitative data generated 
from the audiorecorded interviews with patient–carer 
dyads and clinicians will be analysed using framework 
analysis.25 Audiorecordings of recruitment consultations 
will be analysed using content analysis26 to highlight 
specific issues and enable immediate feedback to the trial 
management group.
Patient and public involvement
Patients have played a central role in the design and 
development of this study. Our early work with the 
Wythenshawe/Christie lung cancer Patient and Public 
Invovlement and Engagement (PPIE) group and North 
Trent Consumer Research Panel clearly supported the 
need for quality of life and burden to be included in 
treatment decision making. The issue of recruitment 
with previous trials comparing surgery with radiotherapy 
has been fully explored with our patient groups. The 
randomisation process was a concern for some patients 
so it will be clearly specified in the patient information 
sheet and at the time of consent that the trial has been 
suggested to them because there was no clear indication 
which treatment would have the best outcome for them. 
Given the patients concern, it was also decided that a 
clinician would lead the recruitment consultation.
Anticipated risks and mitigation
As described earlier, optimising recruitment will be 
addressed using the QRI methodology. Other risks 
include that the treatment paradigm in stage III- N2 
NSCLC may change during the course of this feasibility 
trial (eg, immunotherapy in surgical treatment path-
ways). However, the research question will remain rele-
vant regarding the impact on HRQOL from surgical 
versus non- surgical based multimodality treatment regi-
mens. We have designed this feasibility study in a prag-
matic way which allows different types of regimens within 
each arm that reflect changing standards of care. If we 
can prove this trial is feasible to recruit to then for a 
phase III trial we will need to clearly define the standard 
of care in both the surgical and non- surgical arms that 
reflects the evidence base and guidelines at that moment. 
Finally, data completeness will be important particularly 
in the first 9 weeks where multiple different HRQOL 
questionnaires are needed. The ability to complete this 
information via telephone and the use of reminder tele-
phone calls should help to mitigate this risk.
ETHICS AND DISSEMINATION
The trial has been approved by the West of Scotland 
Research Ethics Committee and Health Research 
Authority. The sponsor and the REC have approved the 
trial protocol, PIS, consent form and submitted supporting 
documents. Any agreed substantial amendments will be 
submitted for ethical approval prior to implementation. 
The trial will be conducted in accordance with the prin-
ciples of Good Clinical Practice. Data will be collected 
and processed in accordance with the Data Protection 
Act 2018. Trial documents will be retained for 5 years 
after the end of the study then they will be destroyed. All 
personal identifiable information will be kept in secure 
password protected electronic files or locked storage 
cabinets. We intend to submit the summary results of the 
feasibility to a peer- reviewed, open- access journal. After 
publication, the deidentified individual patient data will 
be made available on request to researchers who provide 
a methodologically sound proposal.
The current study represents the first randomised trial 
in the N2 lung cancer population to assess quality of life 
and treatment burden as an outcome for both patients 
and family carers. We will disseminate the result of this 
study widely at national and international clinical meet-
ings and academic conferences. We have coapplicants 
that are members of the organising committee for various 
national and international organisations and will ensure 
full dissemination. The trial has already been discussed 
at the EORTC trials meeting with positive feedback and 
a potential to collaborate on a phase III European wide 
trial. We will also engage with patient and public involve-
ment groups, including those who helped to develop the 
application and disseminate results.
CONCLUSION
This feasibility trial aims to provide the pivotal informa-
tion that will inform the design and scale of a phase III 
randomised trial of surgery versus no surgery as part of multi-
modality treatment in stage III- N2 with HRQOL as a primary 
outcome, as well as to determine whether it is feasible to 
recruit patients at the required level to deliver such a trial.
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